Table 4.
Description of injectable regimens, toxicities and discontinuation among participants on MDR-TB treatment follow-up at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia
| Characteristics | N(%) |
|---|---|
| Type of injectable drug used | |
| Capreomycin | 789 (84.7) |
| Kanamycin | 37 (5.6) |
| Amikacin | 40 (4.3) |
| Streptomycin | 2 (0.2) |
| Mean (± SD) duration on injectable treatment (months) | 8.51 ± 2.3 |
| Mean (± SD) total dose of injectables received(g) | 158.5 ± 56.2 |
| Switching of injectable | 49 (5.3) |
| Discontinuation of injectable due to toxicity | 34 (3.9) |
| Hearing disturbance/ototoxicity | 8 (0.9) |
| Nephrotoxicity/clinical renal failure | 26 (2.9) |
| Clinically diagnosed nephrotoxicity | 62 (6.7) |
| Clinically diagnosed ototoxicity | 42 (4.8) |
| Hearing loss | 16 (1.8) |
| Imbalance | 7 (0.8) |
| Visual disturbance | 19 (2.2) |